These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36915587)

  • 1. Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis.
    Hu W; Yang J; Zhang Z; Xu D; Li N
    Transl Cancer Res; 2023 Feb; 12(2):247-256. PubMed ID: 36915587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
    Li X; Wu S; Zhang L; Zhu J; Xu B
    Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
    Yuan Y; Liu X; Cai Y; Li W
    PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study.
    Li F; Xu F; Li J; Wang T; Bian L; Zhang S; Jiang Z
    Ann Transl Med; 2021 Jan; 9(2):103. PubMed ID: 33569405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
    Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
    Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
    Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
    Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
    You S; Sang D; Xu F; Luo T; Yuan P; Xie Y; Wang B
    Ther Adv Med Oncol; 2023; 15():17588359231217972. PubMed ID: 38145113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
    Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
    Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
    Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
    Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
    Liao H; Huang W; Liu Y; Pei W; Li H
    Front Oncol; 2021; 11():608781. PubMed ID: 34012912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study.
    Li F; Liang Y; Luo M; Shen J; Zhou T; Liang Y; Tang X; Yuan H; Zeng J
    Front Oncol; 2023; 13():1041111. PubMed ID: 36793595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.
    Zhang Q; He P; Tian T; Yan X; Huang J; Zhang Z; Zheng H; Zhong X; Luo T
    Front Pharmacol; 2023; 14():1100556. PubMed ID: 37025489
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
    Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
    Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
    Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
    Front Oncol; 2022; 12():855512. PubMed ID: 35463365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
    Hu ZY; Yan M; Xiong H; Ran L; Zhong J; Luo T; Sun T; Xie N; Liu L; Yang X; Xiao H; Li J; Liu B; Ouyang Q
    BMC Med; 2023 Jun; 21(1):226. PubMed ID: 37365596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.